华融化学 reported revenue of ¥0.76B for the period ended 2026-06-30, -1.9% year on year. Net income was ¥0.03B, a 4.1% net margin on a 8.9% gross margin. The largest revenue line is 供应链管理业务 at 52% of the total. Free cash flow for the period was ¥0.03B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.76B | -1.9% |
| Gross profit | ¥0.07B | — |
| Operating income | ¥0.04B | — |
| Net income | ¥0.03B | -5.8% |
| Gross margin | 8.9% | Net margin 4.1% |
| Revenue Q/Q | -44.8% | — |
| Segment | Revenue | Share |
|---|---|---|
| 供应链管理业务 | ¥0.39B | 51.6% |
| 钾产品 | ¥0.31B | 41.6% |
| 氯产品 | ¥0.04B | 5.6% |
| 其他(补充) | ¥0.01B | 1.2% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.69B | 91.1% |
| R&D | ¥0.00B | 0.3% |
| SG&A | ¥0.03B | 3.4% |
| Tax & other | ¥0.01B | 1.0% |
| Item | Amount |
|---|---|
| Total assets | ¥2.26B |
| Total liabilities | ¥0.55B |
| Shareholders' equity | ¥1.71B |
| Equity / assets | 75.8% |
| Operating cash flow | ¥0.04B |
| Capital expenditure | ¥0.00B |
| Free cash flow | ¥0.03B |
| Cash conversion (OCF / net income) | -148% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
普蕊斯 ・ 富士莱 ・ 艾布鲁 ・ 格力博 ・ 恒工精密 ・ 海看股份 ・ 泰恩康 ・ 华新科技 ・ 宇邦新材 ・ 华厦眼科 ・ 铭利达 ・ 汉仪股份
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies